MaxiVAX Information

View Top Employees from MaxiVAX

Release Therapeutics (previously called MaxiVAX) developed a revolutionary, patented, platform technology for the delivery of highly potent therapeutic proteins to the CNS and beyond. Centered on prioritizing patient needs, this novel platform is a promising therapeutic approach, distinguished by its unique CNS-directed functionality and versatile multi-application capabilities.

Website	http://www.maxivax.ch/home/
Revenue	$5 million
Employees	6 (0 on RocketReach)
Founded	2005
Address	Rue de l'Athénée 24, Genève, Genève 1206, CH
Phone	+41 22 552 26 13
Technologies	JavaScript , HTML , PHP +11 more (view full list)
Industry	Biotechnology Research, Chemicals, Petrochemicals, Glass & Gases, Biotechnology, Manufacturing, Drug Discovery
Keywords	Therapeutic Proteins, Protein Therapeutics, Central Nervous System, Protein Delivery, Drug Delivery, Platform Technology, Novel Drug Delivery, Pharmaceutical Technology, Patented Technology, Drug Development, Revolutionary Technology, Pharmaceutical Research, Biotechnology, Biopharma, Innovative Treatments, Medical Technology, Therapeutics, Patient Needs
Competitors	Johnson & Johnson, Merck & Co., Inc., Pfizer, GSK, Sanofi, AstraZeneca, Regeneron, Moderna Therapeutics, Novavax, CureVac +38 more (view full list)
SIC	SIC Code 2834 Companies, SIC Code 283 Companies, SIC Code 28 Companies
NAICS	NAICS Code 32541 Companies, NAICS Code 3254 Companies, NAICS Code 32 Companies, NAICS Code 325 Companies